Browsing Tag
Tempus AI
14 posts
Is Merck & Co., Inc. embedding artificial intelligence at the core of its oncology strategy through Tempus AI integration?
Merck expands its Tempus AI collaboration to embed artificial intelligence into oncology research. What this means for MRK, TEM, and precision medicine.
Avacta (AIM: AVCT) sets 2026 clinical momentum with AVA6103 trial launch and AVA6000 data readouts
Avacta targets dual clinical milestones in 2026 with AVA6103 trial launch and AVA6000 readouts. Find out how its small-molecule platform could reshape oncology.
Avacta Therapeutics (AIM: AVCT) secures FDA clearance for AVA6103 as pre|CISION platform enters its second clinical test
Avacta Therapeutics secures FDA IND clearance for AVA6103, advancing its pre|CISION platform into a second clinical program. Read what changes next.
Tempus joins forces with Whitehawk Therapeutics to power next-gen biomarker-based oncology trials
Find out how Tempus and Whitehawk are using AI and real-world data to transform biomarker-driven oncology—discover the collaboration’s science and market impact.
IREN announces $875mn convertible notes offering to fund AI and mining expansion
Find out how IREN’s $875 million convertible note plan could reshape its AI cloud pivot, mitigate dilution, and influence investor sentiment.
Can AI trial matching close the gap in cancer drug access?
Can AI fix clinical trial access in cancer care? Discover how Tempus, TrialJectory, and CureMatch are using intelligent platforms to democratize treatment pathways.
The business of AI in oncology: Who’s building the platforms hospitals trust?
Tempus, Guardant, Freenome, and Paige are building the AI oncology platforms hospitals now rely on. Discover the financials and future shaping cancer diagnostics.
Brainomix appoints Khush F. Mehta as Chair to accelerate global ai healthcare expansion
Brainomix names Khush F. Mehta as Chair to drive U.S. and global expansion after $18M funding and FDA clearance for its AI stroke platform.
Top U.S. gainers: Regencell, Disney, Rockwell, and Tempus AI spark broad market rally
Explore which U.S. stocks surged on May 7, 2025, and why investors rotated into biotech, AI, and healthcare amid Fed pauses and macro uncertainty.
AI just got personal: Illumina and Tempus team up to make DNA testing part of every doctor’s visit
Find out how Illumina and Tempus are transforming healthcare with AI-driven genomic tools to advance precision medicine across cancer, cardiology, and more.